Navigation Links
Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
Date:4/24/2008

PHOENIX, April 24 /PRNewswire/ -- Latona Life Sciences Inc. (Latona) announced today that it has entered into two agreements for the acquisition of patent rights and orphan drug status to a novel late-stage drug, trademarked "Oralgam," for the treatment of Juvenile and Adult Rheumatoid Arthritis.

Latona has entered into a licensing agreement to acquire the patent rights to Oralgam with Research Corporation Technologies, Inc., of Tucson, Arizona. Under the terms of this agreement, Latona will acquire the exclusive worldwide rights to Oralgam for the treatment of Adult Rheumatoid Arthritis and the treatment of auto-immune induced hearing loss.

Latona has also entered into a purchase and sale agreement to acquire the Orphan Drug Status, clinical data set and trademark to Oralgam with Protein Therapeutics Inc. of Tucson, Arizona. Under the terms of this agreement Latona will acquire the Orphan Drug Status to Oralgam for the treatment of Juvenile Rheumatoid Arthritis, GI Dysfunction in Autism and Dermatomyostis.

"Latona is extremely pleased to acquire the worldwide rights to Oralgam," stated Joseph Koziak, CEO of Latona. "We believe that Oralgam has the potential to provide significant relief to those who suffer from Arthritis and potential other auto-immune disorders."

About Oralgam - Oralgam is a late Phase II drug used for the treatment of immune mediated diseases. A novel product, Oralgam has shown efficacy in the treatment of juvenile arthritis in patients who have had limited success with other known pharmaceutical treatments. A platform technology, Oralgam is expected to be clinically tested in other immune mediated diseases.

About Latona Life Sciences - Latona is a privately held specialty pharmaceutical company dedicated to development and commercialization of immune mediated diseases.

About Research Corporation Technologies (RCT) - RCT (http://www.rctech.com) is a technology, investment and management company that provides early stage funding and development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide. RCT has assets of more than $300 million to advance technology and development through venture investment partnerships and special licensing programs.

For more information:

Joseph Koziak

President and CEO

Latona Life Sciences Inc.

Ph. 480 254 8530

Email: jkoziak@latonalifesciences.com

Michael Schultz

Vice President - Business Development

Latona Life Sciences

Ph. 314 378 2457

Email: mschultz@latonalifesciences.com


'/>"/>
SOURCE Latona Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... 01, 2017 , ... Expert on international living and leading a healthy lifestyle, ... , Time & Go app is the ultimate strategic compass that helps users to ... methods enable people to work smarter, not harder, that's why Time & Go app ...
(Date:3/1/2017)... ... 01, 2017 , ... March 2017 – All year round the treadmill represents ... stop training to brave the cold weather, snow or ice. Treadmill running poses special ... help protect these vulnerable joints, says orthopaedic surgeon Kevin D. Plancher, MD, founder of ...
(Date:3/1/2017)... ... March 01, 2017 , ... “McFarnia”: a suspenseful tale of a father who ... life and mysterious disappearance. “McFarnia” is the creation of published author Tony Pierzchala, a ... currently serves as a Chaplain with Transport for Christ at a truck stop in ...
(Date:3/1/2017)... ... , ... “Letter of Love”: a tale of young love and war. ““Letter ... Civil War in El Salvador, wife, mother, and co-founder of a Christian College. , ... to serve in very poor communities, and I study psychology. I lived the civil ...
(Date:3/1/2017)... ... March 01, 2017 , ... “The Affair is Over Now Go ... emotional upheaval of an extramarital affair. “The Affair is Over Now Go Live Your ... former lay pastor who has dedicated her professional life to teaching and writing about ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... India and PRINCETON, N.J. ... Industries Ltd (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: ... subsidiaries or associate companies) today announced that several ... clinical trials (reSURFACE 1 and 2) of tildrakizumab, ... treatment of moderate-to-severe plaque psoriasis, will be presented ...
(Date:3/1/2017)... March 1, 2017  The Board of Directors of ... Turfe as the new CEO and Chairman of ... of long-time Chairman and CEO William R. Cobb ... nationwide search, and brings a wealth of experience in ... "In a pool of incredibly qualified ...
(Date:3/1/2017)... March 1, 2017 Lo stesso sistema sara, visibile nello ... Paramed Medical Systems sta installando la settima unità MROpen in ... nel nuovo centro dell,European Scanning Center (ESC) a Cardiff. ESC attualmente gestisce altri ... Manchester. Continue Reading ... ...
Breaking Medicine Technology: